Novartis AG
NVS
$125.50
$0.490.39%
NYSE
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 54.35B | 53.26B | 51.72B | 50.32B | 48.59B |
| Total Other Revenue | 2.02B | 1.92B | 1.50B | 1.41B | 1.35B |
| Total Revenue | 56.37B | 55.19B | 53.22B | 51.72B | 49.94B |
| Cost of Revenue | 13.39B | 13.09B | 12.95B | 12.82B | 12.07B |
| Gross Profit | 42.98B | 42.10B | 40.28B | 38.91B | 37.87B |
| SG&A Expenses | 13.30B | 13.13B | 12.78B | 12.57B | 12.48B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 326.00M | 1.03B | 1.29B | 1.52B | 930.00M |
| Total Operating Expenses | 37.44B | 37.21B | 36.72B | 36.66B | 32.87B |
| Operating Income | 18.93B | 17.98B | 16.50B | 15.07B | 17.07B |
| Income Before Tax | 16.42B | 15.61B | 14.92B | 13.64B | 12.73B |
| Income Tax Expenses | 2.04B | 1.97B | 2.06B | 1.70B | 975.00M |
| Earnings from Continuing Operations | 14.38K | 13.64K | 12.86K | 11.94K | 11.76K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | 5.84B |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 10.00M | 16.00M | -1.00M | 2.00M | 4.00M |
| Net Income | 14.39B | 13.65B | 12.86B | 11.94B | 17.60B |
| EBIT | 18.93B | 17.98B | 16.50B | 15.07B | 17.07B |
| EBITDA | 22.40B | 21.35B | 19.83B | 18.41B | 21.40B |
| EPS Basic | 7.36 | 6.91 | 6.43 | 5.92 | 8.63 |
| Normalized Basic EPS | 5.78 | 5.45 | 4.96 | 4.46 | 5.03 |
| EPS Diluted | 7.31 | 6.86 | 6.39 | 5.88 | 8.58 |
| Normalized Diluted EPS | 5.75 | 5.41 | 4.92 | 4.43 | 5.00 |
| Average Basic Shares Outstanding | 7.83B | 7.92B | 8.00B | 8.08B | 8.14B |
| Average Diluted Shares Outstanding | 7.88B | 7.97B | 8.06B | 8.13B | 8.19B |
| Dividend Per Share | 3.86 | 3.86 | 3.86 | 3.86 | 3.92 |
| Payout Ratio | 54.32% | 57.26% | 60.27% | 63.85% | 43.31% |